MoonLake advances sonelokimab toward BLA after positive FDA meeting

MoonLake Immunotherapeutics ( (MLTX) ) has shared an update.

MoonLake Immunotherapeutics reported that an April 1, 2026 final pre-BLA meeting with the U.S. FDA for sonelokimab in hidradenitis suppurativa yielded a positive outcome, with agreement on submission plans, label strategy and inclusion of adolescent data. The FDA confirmed the MIRA trial as key to establishing substantial evidence of effectiveness and backed inclusion of VELA-TEEN and VELA safety data, paving the way for a Biologics License Application submission planned for late September 2026.

The proposed HS label is expected to highlight the MIRA trial’s roughly 43% HiSCR75 response and about 29 percentage point advantage over placebo at week 12, described as the strongest results seen in adequately controlled HS trials to date. With no remaining regulatory gaps identified and a potential first U.S. launch targeted for the second half of 2027, MoonLake also reported first-quarter 2026 cash and investments of $357.9 million and access to a $400 million debt facility, supporting a pipeline of upcoming Phase 3 readouts in HS and psoriatic arthritis that could significantly shape its competitive position.

The most recent analyst rating on (MLTX) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on MoonLake Immunotherapeutics stock, see the MLTX Stock Forecast page.

Spark’s Take on MLTX Stock

According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, accelerating losses and cash burn, and rising debt), partly offset by positive corporate catalysts (favorable FDA feedback and strong Phase 2 data) and a mixed-to-slightly constructive momentum picture. Valuation inputs are not very informative due to negative earnings and no dividend.

To see Spark’s full report on MLTX stock, click here.

More about MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company based in Zug, Switzerland, developing sonelokimab, an investigational Nanobody® targeting IL-17A and IL-17F for inflammatory diseases. Its pipeline focuses on conditions with significant unmet need such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis, pursuing multiple dermatology and rheumatology indications including adolescent HS.

Nanobody-based therapies like sonelokimab are designed to leverage small size, enhanced tissue penetration and multivalent formats for improved efficacy and manufacturability. MoonLake’s strategy centers on positioning sonelokimab as a next-generation targeted treatment across inflammatory indications, aiming to differentiate on clinical response depth, safety profile and the breadth of patient populations covered, including younger patients.

Average Trading Volume: 1,113,329

Technical Sentiment Signal: Sell

Current Market Cap: $1.24B

See more insights into MLTX stock on TipRanks’ Stock Analysis page.